Abiopharma

Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma

Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma

Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

Pfizer’s BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer

Pfizer’s BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer

Investor Presentation - Q1 2026 - Periodic report amendment

Financial statements as of 31.3.26 of the third fund for investments in multi-family housing in the US of the company

Ceased to be an interested party - Leon Recanati

Capital market presentation - Q1 202 summary

Change/cancellation of a purchase plan